MedPath

Effect of Exercise and Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause

Phase 3
Terminated
Conditions
Coronary Disease
Metabolic Syndrome X
Bone Diseases
Interventions
Behavioral: wellness control, placebo
Behavioral: exercise
Behavioral: exercise + cimicifuga racemosa
Registration Number
NCT00663104
Lead Sponsor
University of Erlangen-Nürnberg Medical School
Brief Summary

The aim of the study is to compare the effect of a progressive, periodized exercise training designed to impact bone, CHD-risk-factors and menopausal complaints versus the combined effect of exercise and "phytoestrogen" (cimicifuga racemosa; CR). After randomization, 84 females 1-3 year postmenopausal with no medication or illness affecting bone metabolism exercise over 12 months (EG; 42 with, 42 without CR), 42 women serve as wellness-control. Three group training sessions/week will be performed in the EG. Both groups will be individually supplemented with calcium and Vit-D (cholecalciferol).

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
126
Inclusion Criteria
  • 1-3 years early postmenopausal
  • Caucasian race
Exclusion Criteria
  • CHD-diseases
  • thrombosis, embolism
  • fractures at lumbar spine or hip
  • secondary osteoporosis
  • hyperparathyroidism
  • medication, diseases with impact on muscle or bone
  • cancer and hormone derived malign diseases
  • weight reduction of > 5 kg during the last 6 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
3wellness control, placebowellness control, placebo
1exerciseexercise (3 sessions/week)
2exercise + cimicifuga racemosaexercise and "phytoestrogen" (cimicifuga racemosa)
Primary Outcome Measures
NameTimeMethod
Bone Mineral Densitybaseline, 12 month
Secondary Outcome Measures
NameTimeMethod
body compositionbaseline, 12 month
blood lipids, glucosebaseline, 12 month
blood pressurebaseline, 12 month
10 year CHD-riskbaseline, 12 months
menopausal complaintsbaseline, 12 months

Trial Locations

Locations (1)

Institute of Medical Physics

🇩🇪

Erlangen, Germany

© Copyright 2025. All Rights Reserved by MedPath